Ocuphire Pharma Results

IVT Anti-VEGF Therapies are Standard of Care for AMD/DME Anti-VEGF Therapies Over the Decades; Limited Use in DR Patients Ocuphire PHARMA 2004 Pegaptanib nAMD MÄCUGENⓇ PEGAPTANIB SODIUM INJECTION 2006 Source: Company websites Ranibizumab nAMD LUCENTISⓇ RANIBIZUMAB INJECTION 2011 Aflibercept nAMD EYLEAⓇ (aflibercept) Injection For Intravitreal Injection 2012 Ranibizumab DME LUCENTIS® RANIBIZUMAB INJECTION MOA focused on VEGF and local delivery have demonstrated efficacy for approved treatments, are the current standard of care, and have been highly effective for wAMD/DME. However, these therapies have limited use in DR 2014 Aflibercept DME EYLEA (aflibercept) Injection For Intravitreal Injection 2019 Brolucizumab- dbll AMD Beovu. (brolucizumab-dbll) Injection EYLEA (aflibercept) Injection For Intravitreal Injection LUCENTIS® RANIBIZUMAB INJECTION 2022 Faricimab- svoa nAMD/DME VABYSMO faricimab-svoa injection 6 mg $9b+ 2021 Revenue $2b+ 2021 Revenue 21

View entire presentation